Introduction
Allogeneic hematopoietic cell transplantation has been established as a curative therapy for hematological malignancies. 1, 2 Because of the better understanding of the significance of HLA allele compatibility and the advances in supportive care, the results of BMT from unrelated donors are improving. [3] [4] [5] Cell dose is one of the major factors that can be manipulated by physicians and affect transplant outcomes. [6] [7] [8] Historically, its importance for engraftment and hematological recovery has been documented in patients with aplastic anemia. 9, 10 Several subsequent studies showed that cell dose was also associated with better survival due to decreased nonrelapse mortality (NRM) in hematological malignancies. However, other important factors, such as patient age, disease, conditioning, GVHD prophylaxis, ABO compatibility, donor characteristics and HLA matching, also affect the transplant outcome. 11, 12 Therefore, the actual effect of cell dose should be confirmed after adjustment for all of these factors with a sufficient number of patients.
On the other hand, the GVL effect may work differently according to disease stages. Rocha et al. 13 showed that cell dose was associated with decreased relapse rates in AML in first CR, whereas no significant associations between cell dose and relapse rates were observed in other studies, including various diseases. 7, 8, 11 These conflicting results suggested that the cell dose effect is worth analyzing separately according to disease stages.
In this report, we examined adjusted effects of cell dose on various transplant outcomes according to disease stages and children or adults using the detailed registry data of 3559 patients who received T-cell replete unrelated BMT through the Japan Marrow Donor Program.
Patients and methods

Patients
The data set consisted of 5071 unrelated BMTs facilitated by the Japan Marrow Donor Program between 1993 and 2005. Of these 5071 patients, 3559 with AML, ALL, CML and myelodysplastic syndrome who received their first T-cell replete myeloablative transplantation with GVHD prophylaxis containing calcineurin inhibitor without antithymocyte globulin were selected for this study. The patients and donors were all Japanese. Informed consent for this registry study was obtained from patients and donors in accordance with the declaration of Helsinki. This study was approved by the data management committees of Japan Marrow Donor Program.
Transplantation procedure
Patients were conditioned with various regimens determined by each transplant center. The proportions of TBI regimen were assessed from the database. Red cells and/or plasma removal from the graft was performed for ABOmajor and/or -minor mismatched transplantation. All grafts were BM because the donation of PBSCs from unrelated donors is not yet approved in Japan. GVHD prophylaxis was categorized into either a CsA-based or tacrolimus-based prophylaxis.
HLA matching HLA-A, -B and -DRB1 alleles were identified by highresolution DNA typing as described previously. 3, 4 As our previous study showed that a single-allele mismatch at DRB1 locus had no impact on engraftment, acute and chronic GVHD, NRM, relapse and OS in the Japanese population, 4 it was considered as a HLA-matched transplantation in this study.
Definition of disease stage and outcomes
Early stage was defined as the status of the first and second CR of AML and ALL, the first chronic phase of CML and refractory anemia of myelodysplastic syndrome, whereas advanced stage was defined as other status. For cytogenetic categorization, patients were divided into three categories: good risk (AML with t(15;17), inv16 or t(8;21)), intermediate risk (other than good or poor risk) or poor risk (ALL with t(9;22) or t(4;11), CML with additional abnormalities other than t(9;21) or myelodysplastic syndrome with complex or chromosome 7 abnormalities). 14 Engraftment was defined as an ANC of more than 500/ml for 3 consecutive days in the peripheral blood, and analyzed among all patients. Acute GVHD was graded by established criteria. 15 Chronic GVHD was assessed in patients surviving beyond day þ 100, and was classified as limited or extensive according to the Seattle criteria. 16 
Statistical analysis
Cell dose was defined as harvested total nucleated cell dose. Analysis was performed separately for disease stages, and children or adults. Children were defined as patients who were aged 12 years or younger for two reasons. One reason was because cell dose per patient body wt had a stronger linear correlation with age at these ages. Another reason was because patients aged 12 years or younger were usually treated with children's protocols. To determine the impacts of low and high cell doses on the outcomes in the current practices, cut-off points were set at upper and lower 25% of the cell dose separately in children and adults. Patient characteristics and causes of NRM were tested for associations using the w 2 -test for discrete variables, and the Spearman rank correlation test for continuous variables. Cumulative incidences of NRM, relapse and GVHD were estimated by Gray's method. Relapse was considered as a competing risk in NRM, deaths without relapse as a competing risk in relapse, and deaths without GVHD as a competing risk in GVHD. OS was calculated using the Kaplan-Meier method and P-values were calculated using a Log-rank test. Multivariate analyses were performed using logistic regression model for engraftment, the Cox proportional hazard regression model for OS, and the multivariate proportional hazard modeling of subdistribution functions in competing risks for NRM, relapse and GVHD. 17 Variables considered in the analysis were cell dose, patient age (linear), ABO incompatibility (none, major or minor), disease stage (early or advanced), cytogenetics (good, intermediate or poor), the number of HLA-mismatched loci, patient sex, donor sex, female to male transplantation, conditioning (TBI regimen, antithymocyte globulin regimen, and reduced-intensity regimen), GVHD prophylaxis (CsA-based or tacrolimus-based), donor age (linear), year of transplant (categorical) and preceding grades II-IV acute GVHD (only for chronic GVHD analysis). Cell dose was kept in the final model even though it was not statistically significant. All statistical tests were two-sided, and P-values less than 0.05 were considered significant. Analysis was performed using STATA (Stata Statistical Software: Release 10.0., Stata Corporation, College Station, TX, USA) and R version 2.10.0 (The R Foundation for Statistical Computing, Vienna, Austria).
Results
Patient characteristics
The number of patients with AML, ALL, CML and myelodysplastic syndrome were 1205 (34%), 1140 (32%), 755 (21%) and 459 (13%), respectively. The median volumes of harvested marrow for child and adult recipients were 426 mL (range, 83-1045) and 850 mL (range, 220-1500), respectively (Po0.0001). The median numbers of harvested cells for child and adult recipients were 3.63 Â 10 Tables 1 and 2 . Recipient age, recipientdonor gender compatibility, recipient body wt, GVHD prophylaxis and the year of transplantation showed statistically significant differences according to cell dose in children. Recipient age, recipient-donor gender compatibility, recipient body wt, ABO mismatch, disease type in early-stage malignancy, GVHD prophylaxis and the year of transplantation showed statistically significant differences according to cell dose in adults.
Engraftment
Engraftment was achieved in 500 of 516 (97%) child patients and 2882 of 3043 (95%) adult patients. Multivariate analysis showed that o3.0 Â 10 8 /kg was associated with lower engraftment rates in children with advanced-stage diseases (odds ratio, 0.15; 95% confidence interval (CI), 0.03-0.74; P ¼ 0.02) and o2.3 Â 10 8 /kg was associated with lower engraftment rates in adults with advanced-stage diseases (odds ratio, 0.60; 95% CI, 0.37-0.97; P ¼ 0.039). Abbreviation: MDS ¼ myelodysplastic syndrome.
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Acute and chronic GVHD The cumulative incidences of grades II-IV acute GVHD in children and adults were 50 and 43%, respectively.
Multivariate analysis showed no statistically significant association of cell dose with incidences of grades II-IV acute GVHD in children and adults. Table 3 Variables associated with relapse in (a) children and (b) adults The cumulative incidences of limited or extensive chronic GVHD in children and adults were 34 and 45%, respectively. Multivariate analysis in children showed a statistically significant association of o3.0 Â 10 8 /kg with higher incidences of chronic GVHD in advanced-stage diseases (hazard ratio, 2.46; 95% CI, 1.17-5.17; P ¼ 0.017). Multivariate analysis in adults showed no statistically significant association of cell dose with incidences of chronic GVHD.
NRM
The cumulative incidences of NRM at 5 years in children and adults were 21 and 39%, respectively. Multivariate analysis showed no statistically significant association of cell dose with incidences of NRM in children (Supplementary Table S1a ) and adults (Supplementary Table S1b ). Causes of NRM according to cell dose were not statistically different in children. As a cause of NRM in adults, the proportions of idiopathic pneumonia syndrome were statistically different according to cell dose (13, 14 and 23% for o2.3, 2.3-3.4 and 43.4 Â 10 8 /kg, respectively; P ¼ 0.002).
Relapse
The cumulative incidences of relapse at 5 years in children and adults were 27 and 25%, respectively. Multivariate analysis in children showed no statistically significant association of cell dose with incidences of relapse (Table 3a) . Multivariate analysis in adults showed a statistically significant association of 43.4 Â 10 8 /kg with lower incidences of relapse in early-stage diseases (hazard ratio, 0.60; 95% CI, 0.43-0.85; P ¼ 0.004) (Table 3b) . Results were similar when CML in chronic phase was excluded from analysis in adults (data not shown).
OS
The median follow-up periods among survivors were 57 months (range, 9-140 months) in children and 55 months (range, 3-147 months) in adults. The OS rates at 5 years among children with early-stage diseases were 67, 75 and 68% for o3.0, 3.0-4.6 and 44.6 Â 10 8 /kg, respectively (P ¼ 0.74; Figure 1a ). The OS rates at 5 years among children with advanced-stage diseases were 31, 36 and 40% for o3.0, 3.0-4.6 and 44.6 Â 10 8 /kg, respectively (P ¼ 0.46; Figure 1b ). The OS rates at 5 years among adults with early-stage diseases were 54, 57 and 65% for o2.3, 2.3-3.4 and 43.4 Â 10 8 /kg, respectively (P ¼ 0.0029; Figure 1c ). The OS rates at 5 years among adults with advanced-stage diseases were 26, 28 and 31% for o2.3, 2.3-3.4 and 43.4 Â 10 8 /kg, respectively (P ¼ 0.27; Figure 1d ).
Multivariate analysis in children showed no statistically significant association of cell dose with survival rates (Table 4a ). Multivariate analysis in adults showed a statistically significant association of 43.4 Â 10 8 /kg with better survival rates only in early-stage diseases (hazard ratio, 0.74; 95% CI, 0.62-0.90; P ¼ 0.002) (Table 4b) .
Discussion
This study showed that effects of cell dose on transplant outcomes were different among disease stages. Among children, we could not show any statistically significant effects of cell dose except the lower engraftment rates and higher incidences of chronic GVHD associated with o3.0 Â 10 Although many studies reported that higher cell dose improved OS rates, 8, 11, 12, 18, 19 effects of cell dose on relapse and NRM rates were not consistent among studies probably because of the differences in diseases, stages and transplant procedures. Furthermore, it is not practical to analyze child and adult patients together because biology of disease, treatment protocols and harvested total nucleated cells per body wt are likely to differ between them. Therefore, we investigated cell dose effects separately according to disease stages and children or adults, and extended analysis to various outcomes.
Although several studies showed that engraftment rates were improved with higher cell dose, 6,11 our results did not show any statistically significant merits with high cell dose both in children and adults. Low cell dose was associated with worse engraftment rates in advanced-stage diseases in both children and adults. Effects of low cell dose would be particularly great in advanced-stage diseases considering that graft failure occurs more frequently in advanced-stage diseases. 7 Effects of cell dose on relapse rates were controversial. Although several studies did not show any effects of cell dose on relapse rates, 7, 8, 11 the results of our study supported those by Rocha et al. 13 among patients with AML in the first CR, and those by Barrett et al. 20 after Cell dose effects in unrelated BMT Y Inamoto et al Table 4 Variables associated with OS in (a) children and (b) adults Cell dose effects in unrelated BMT Y Inamoto et al identical twin BMT. Interestingly, our results showed lower relapse rates not associated with higher incidences of acute GVHD, which was also observed in the studies by Rocha et al. 13 and by Barrett et al. 20 GVL effect is influenced by disease types and stages possibly because of the differences in expression of tumor Ags, co-stimulatory molecules, resistance to killing and growth patterns. 21, 22 It has been demonstrated that the GVL effect works more efficiently for minimal residual disease than for active disease. 23, 24 Therefore, it is reasonable that decreased relapse rates with X3.4 Â 10 8 /kg was limited to early-stage diseases. Although it may be argued that patients with CML in chronic phase greatly influence the outcomes, 25 the results were similar even if these patients were excluded from analysis.
What are effector cells of cell dose effect? Calculated with the published data, 26 [27] [28] [29] this number of T cells can alter the outcome but that of nature killer cells will not. Therefore, we speculated that T cells would be the most likely population affecting relapse rates. As the registry did not have data as to graft composition during the study period, we could not confirm this hypothesis in our data. Using total nucleated cells as the surrogate for cell dose may have limitations because some studies showed that more specific fractions, such as CD34 þ cell dose also predicted transplant outcomes. 30, 31 Future studies analyzing the effect of subpopulations in grafts are warranted.
Many previous studies reported that higher cell dose decreased NRM, particularly related to infection. 7, 8, 12, 32 However, no significant effects of cell dose on NRM rates were observed in our study. To address this discrepancy, we performed a further analysis on causes of NRM according to cell dose, which showed no significant differences in the proportions of deaths from infection both in children and adults. This would partly account for the discrepancy.
In light of the study which reported that 7 Â 10 7 /kg nucleated cells are enough to induce GVHD after donor leukocyte infusion, 33 higher cell dose may result in increased incidences of GVHD. However, most of the previous studies showed that cell dose had no effect on acute GVHD or that higher cell dose decreased acute GVHD. 7, 8, 18 They speculated a possible effect of accessory cells, such as MSCs, and a possibility that higher cell dose decreased early post transplant infections that might There are two possible explanations for the discrepancy observed with regard to the effect of cell dose on OS in children and adults. First, a much greater volume of harvested marrow for adults as compared with children (almost twice the volume) might bring about higher contamination of peripheral blood and increase the dose of graft T cells to produce the different effects. 34 Second, cell dose effect might be already saturated in children because most children received much more cell dose than adults (7 Â 10 7 /kg more at median). Different analytical power between children and adults would not account for the discrepancy as the point estimate of hazard ratio in children with early-stage diseases was more than 1.0 with 44.6 Â 10 8 /kg (Table 4a ). In summary, our results suggested a strategy to determine an optimal cell dose of BMT according to disease stages to maximize the efficacy of BMT and minimize the risk of donors, although these results should be interpreted with caution because of their retrospective nature. In terms of overall benefits, cell dose of 3.4 Â 10 8 /kg or higher is recommended only for adults with early-stage diseases. With the number of patients available for analysis in our study, we could not show any significant benefits associated with 4.6 Â 10 8 /kg or higher in children.
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